AUG 08, 2015 05:56 PM PDT

Bench to Bedside

Researchers Amber Southwell, Michael Hayden and Blair Leavitt at the University of British Columbia Centre for Molecular Medicine and Therapeutics and the Centre for Huntington Disease in Canada have developed a new test that enables physicians to measure the effects of gene silencing therapy in Huntington's disease. The researchers, who worked with colleagues from the Mayo Clinic, will support the first human clinical trial of a drug that targets the genetic cause of the disease. The gene silencing therapy is designed to reduce the levels of a toxic protein in the brain that causes Huntington's disease, as published in Scientific Reports and reported in Drug Discovery & Development (http://www.dddmag.com/news/2015/08/scientists-develop-test-measure-effectiveness-treatments-huntingtons-disease?et_cid=4724062&et_rid=45505806&location=top).
Blair Leavitt of UBC's Centre for Molecular Medicine and Therapeutics , one of the developers of the test
As explained by the American Speech-Language-Hearing Association (ASHA), Huntington's disease (HD) is a genetic disorder characterized by progressive degeneration of brain cells. Most individuals with Huntington's disease develop some signs and symptoms by the time they reach their 30s or 40s. The effects of Huntington's disease include difficulty in motor control (movement), cognition (thinking) and behavior. Sometimes people with HD will the same areas of difficulty throughout the course of the disease, with varying severity. Motor problems in HD include impairments in voluntary movements and uncontrolled involuntary jerking or writhing movements (chorea). Individuals with HD usually experience have muscle problems, such as rigidity or muscle contracture (dystonia), in addition to impaired gait, posture and balance. Motor control problems give those with HD trouble performing daily activities and remaining independent. There can be speech and swallowing problems when the centers of motor or cognitive control responsible for these functions are affected (http://www.asha.org/public/speech/disorders/HuntingtonsDisease.htm).

According to Leavitt, "This is an important breakthrough for several promising gene silencing therapies in Huntington's disease that are now moving from the bench to the bedside. We can move forward with these clinical trials and accurately measure whether our treatments are working."

The genetic mutation that causes HD produces a toxic form of a protein called huntingtin, which progressively damages brain cells. By lowering the brain levels of this toxic protein, researchers hope to prevent or delay the onset of HD symptoms. Several huntingtin-lowering therapies have demonstrated great potential in animal models and are quickly approaching clinical trials in humans.

The team found a way to determine the levels of mutant huntingtin protein in the brain by collecting cerebrospinal fluid from a spinal tap. The ultrasensitive test is designed to detect small amounts of the toxic protein. The test can be used to track changes in brain levels of the protein over time in response to new drugs.

Because of this study, Leavitt can initiate a new clinical trial of a huntingtin gene-silencing therapy for patients at the Centre for Huntington Disease at the Djavad Mowafaghian Centre for Brain Health, a partnership between UBC and Vancouver Coastal Health. This trial, which will test the safety of a novel gene-silencing treatment in patients and is already in the process of screening patient candidates, will be the first human study of a drug targeting mutant huntingtin.
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
NOV 07, 2018
Immunology
NOV 07, 2018
Inflammation Can Steal Your Sleep
A link between inflammation and the circadian rhythm has been determined in mouse models. High-fat-diets may be the cause....
NOV 26, 2018
Neuroscience
NOV 26, 2018
Ventromedial Prefrontal Cortex Central For Imagination Mitigated Fear
Extinction; presenting fear in a neutral setting where the negative consequences are negated is one of the successful fear conditioning mechanisms...
NOV 26, 2018
Neuroscience
NOV 26, 2018
Behavior Predicting Neural Code Identified
Perceptual choice behavior, taking action based on the information received from the senses is often described by mathematical models...
DEC 03, 2018
Neuroscience
DEC 03, 2018
Genes Involved In Dementia Identified
Genetic factors have also been recognized as a critical contributor for dementia and identifying these genes will eventually allow for gene-specific therapeutics to be developed. Although sci...
DEC 18, 2018
Health & Medicine
DEC 18, 2018
Gender Dysphoria
  Gender dysphoria is a distressing conflict for a person whose sexual identity is different than that assigned at birth. Previously called gende...
JAN 11, 2019
Drug Discovery
JAN 11, 2019
Histamine Improves Long-Term Memory
A recent research study found that histamine could improve people’s long-term memory which may be a prospective treatment option to alleviate symptom...
Loading Comments...